Rizatriptan: A pharmacoeconomic review of its use in the acute treatment of migraine

PharmacoEconomics

Volumn 23, Issue 12, 2005, Pages 1283-1298

  McCormack, Paul L ^a   Foster, Rachel H ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

Cost effectiveness; Cost of illness; Migraine; Pharmacoeconomics; Rizatriptan; Therapeutic use; Tolerability

Indexed keywords

ALMOTRIPTAN; ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; CAFERGOT; CODEINE; ELETRIPTAN; ERGOT DERIVATIVE; MAXALT-MELT; MAXALT-MLT; NARATRIPTAN; NARCOTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; RIZATRIPTAN; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ANALGESIA; ASTHENIA; CLINICAL TRIAL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIZZINESS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; DRUG USE; EMPLOYEE; EMPLOYER; FATIGUE; FUNCTIONAL DISEASE; HEALTH CARE; HUMAN; INTERMETHOD COMPARISON; META ANALYSIS; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; PHOTOPHOBIA; POSTAL MAIL; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT; REVIEW; SOMNOLENCE; SPAIN; STATISTICAL MODEL; SYMPTOM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED STATES; WITHDRAWAL SYNDROME; WORKPLACE;

ECONOMICS, PHARMACEUTICAL; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN AGONISTS; TRIAZOLES; TRYPTAMINES;

EID: 29144458180     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523120-00011     Document Type: Review

References (62)

1. Silberstein SD. Migraine. Lancet 2004 Jan 31; 363 (9406): 381-91
2. Adelman JU, Von Seggern RL, Mannix LK. Migraine headaches: implications for management from a nationwide patient survey. Headache Q 2000; 11 (2): 105-12
3. Mychaskiw M, Sankaranarayanan J, Heenan P. Indirect costs due to migraine in the United States [abstract] Value Health 2003 Nov; 6 (6): 763.
4. Plus poster presented at the ISPOR Sixth Annual European Congress; 2003 Nov 9-11; Barcelona
5. Hu XH, Markson LE, Lipton RB, et al. Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999 Apr 26; 159: 813-8
6. de Lissovoy G, Lazarus SS. The economic cost of migraine: present state of knowledge. Neurology 1994 Jun; 44 Suppl. 4: S56-62
7. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul; 41 (7): 646-57
8. Lipton RB, Stewart WF. Prevalence and impact of migraine. Neurol Clin 1997 Feb; 15 (1): 1-13
9. Lipton RB, Stewart WF, Scher AI. Epidemiology and economic impact of migraine. Curr Med Res Opin 2001; 17 Suppl. 1: s4-12
10. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology 2002 Jul 23; 59 (2): 232-7
11. Rasmussen BK, Jensen R, Schroll M, et al. Epidemiology of headache in a general population: a prevalence study. J Clin Epidemiol 1991; 44 (11): 1147-57
12. Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 hours. J Manag Care Pharm 2003 Jan; 9 (1): 45-52
13. Goadsby PJ. The pharmacology of headache. Prog Neurobiol 2000; 62: 509-25
14. Wellington K, Plosker GL. Rizatriptan: an update of its use in the management of migraine. Drugs 2002; 62 (10): 1539-74
15. Lipton RB, Scher AI, Steiner TJ, et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003 Feb 11; 60: 441-8
16. Stang PE, Osterhaus JT. Impact of migraine in the United States: data from the National Health Interview Survey. Headache 1993 Jan; 33: 29-35
17. Terwindt GM, Ferrari MD, Tijhuis M, et al. The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000 Sep 12; 55 (5): 624-9
18. Lipton RB, Hamelsky SW, Kolodner KB, et al. Migraine, quality of life, and depression: a population-based case-control study. Neurology 2000 Sep 12; 55 (5): 629-35
19. D'Amico D, Usai S, Grazzi L, et al. The impact of primary headaches on patients' lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care 2004; 1 (2): 123-8
20. Dueland AN, Leira R, Burke TA, et al. The impact of migraine on work, family, and leisure among young women: a multinational study. Curr Med Res Opin 2004 Oct; 20 (10): 1595-604
21. Gerth WC, Carides GW, Dasbach EJ, et al. The multinational impact of migraine symptoms on healthcare utilisation and work loss. Pharmacoeconomics 2001; 19 (2): 197-206
22. Dooley M, Faulds D. Rizatriptan: a review of its efficacy in the management of migraine. Drugs 1999 Oct; 58: 699-723
23. Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine: a placebo-controlled, dose-ranging study. Dutch/US Rizatriptan Study Group. Arch Neurol 1996 Nov; 53: 1132-7
24. Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997; 17: 647-51
25. Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group. Cephalalgia 1999; 19: 525-30
26. Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence: a placebo-controlled, outpatient study. Rizatriptan 022 Study Group. Headache 1998 Apr; 38: 281-7
27. Lines C, Visser WH, Vandormael K, et al. Rizatriptan 5 mg versus sumatriptan 50 mg in the acute treatment of migraine. Rizatriptan/Sumatriptan Comparison Study Group [abstract]. Headache 1997 May; 37 (5): 319-20
28. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 1998 Nov; 38: 748-55
29. Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Rizatriptan-Naratriptan Study Group. Eur Neurol 1999; 42 (3): 173-9
30. Pascual J, Vega P, Diener HC, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 2000 Jun; 20 (5): 455-61
31. Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Rizatriptan Multiple Attack Study Group. Neurology 1998 Sep; 51: 773-81
32. Goldstein J, Ryan R, Jiang K, et al. Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 1998; 38 (10): 737-47
33. Kolodny A, Polis A, Battisti WP, et al. Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25mg and 50mg tablets. Rizatriptan Protocol 052 Study Group. Cephalalgia 2004 Jul; 24 (7): 540-6
34. Christie S, Gobel H, Mateos V, et al. Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine/caffeine in migraine. Rizatriptan-Ergotamine/Caffeine Preference Study Group. Eur Neurol 2003; 49 (1): 20-9
35. Silberstein SD. Rizatriptan versus usual care in long-term treatment of migraine. Neurology 2000; 55 (9 Suppl. 2): S25-8
36. Block GA, Goldstein J, Polis A, et al. Efficacy and safety of rizatriptan versus standard care during long-term treatment for migraine. Rizatriptan Multicenter Study Groups. Headache 1998 Nov; 38: 764-71
37. Göbel H, Heinze A, Heinze-Kuhn K, et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70 527 patient episodes. Headache 2001 Mar; 41: 264-70
38. Jamieson D, Cutrer FM, Goldstein J, et al. Real-world experiences in migraine therapy with rizatriptan. United States Migraine Study Protocol (USMAP) Group. Headache 2003; 43 (3): 223-30
39. Silberstein SD, Massiou H, McCarroll KA, et al. Further evaluation of rizatriptan in menstrual migraine: retrospective analysis of long-term data. Headache 2002 Oct; 42 (9): 917-23
40. Hu XH, Raskin NH, Cowan R, et al. Treatment of migraine with rizatriptan: when to take the medication. United States Migraine Study Protocol (USMAP) Group. Headache 2002 Jan; 42 (1): 16-20
41. Mathew NT, Kailasam J, Meadors L. Early treatment of migraine with rizatriptan: a placebo-controlled study. Headache 2004 Jul; 44 (7): 669-73
42. Pascual J, García-Moncó C, Roig C, et al. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference. eMAX Study Group. Headache 2005 Oct; 45 (9): 1140-50
43. Lainez MJ, Lopez A, Pascual AM. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study. Headache 2005 Jul; 45 (7): 883-90
44. Merck & Co. Inc. MAXALT® (rizatriptan benzoate): US prescribing information [online]. Available from URL: http:// www.maxalt.com/maxalt/shared/ documents/english/pi.pdf [Accessed 2005 Jun 14]
45. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia 2004; 24 (6): 483-90
46. Krymchantowski AV. Overuse of symptomatic medications among chronic (transformed) migraine patients: profile of drug consumption. Arq Neuropsiquiatr 2003; 61 (1): 43-7
47. Katsarava Z, Fritsche G, Muessig M, et al. Clinical features of withdrawal headache following overuse of triptans and other headache drugs. Neurology 2001 Nov 13; 57 (9): 1694-8; comment + reply 1443-4
48. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 Nov 17; 358: 1668-75
49. Roon KI, Lipton RB, Goadsby PJ, et al. Efficacy of six oral triptans at 1 h post-dose: a meta-analysis [abstract no. P2-K1]. Cephalalgia 2001 May; 21: 405
50. Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001; 4: 105-25
51. Zhang L, Hay JW. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot® in the acute treatment of migraine. CNS Drugs 2005; 19 (7): 635-42
52. Thompson M, Gawel M, Desjardins B, et al. An economic evaluation of rizatriptan in the treatment of migraine. Pharmacoeconomics 2005; 23 (8): 837-50
53. Williams P, Reeder CE. Cost-effectiveness of almotriptan and rizatriptan in the treatment of acute migraine. Clin Ther 2003 Nov; 25 (11): 2903-19
54. Mullins CD, Weis KA, Perfetto EM, et al. Triptans for migraine therapy: a comparison based on number needed to treat and doses needed to treat. J Manag Care Pharm 2005 Jun; 11 (5): 394-402
55. Belsey JD. Cost effectiveness of oral triptan therapy: a transnational comparison based on a meta-analysis of randomised controlled trials. Curr Med Res Opin 2004 May; 20 (5): 659-69
56. Gracia-Naya M. Cost-effectiveness of treatment with triptanes in Spain [in Spanish]. Rev Neurol 2001 Nov; 33 (10): 921-4
57. Gracia-Naya M, Rejas Gutiérrez J, Latorre Jiménez A, et al. Economic evaluation of acute migraine attack treatment with triptans in Spain [in Spanish]. Neurologia 2005 Apr; 20 (3): 121-32
58. Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am J Manag Care 2002 Feb; 8 (3 Suppl.): S80-4
59. Vicente-Herrero T, Burke TA, Lainez MJA. The impact of a worksite migraine intervention program on work productivity, productivity costs, and non-workplace impairment among Spanish postal service employees from an employer perspective. Curr Med Res Opin 2004 Nov; 20 (11): 1805-14
60. Gerth WC, Sarma S, Hu XH, et al. Productivity cost benefit to employers of treating migraine with rizatriptan: a specific worksite analysis and model. J Occup Environ Med 2004 Jan; 46 (1): 48-54
61. Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med 1997 Apr; 39 (4): 320-7
62. Davies GM, Santanello N, Gerth W, et al. Validation of a migraine work and productivity loss questionnaire for use in migraine studies. Cephalalgia 1999 Jun; 19: 497-502